

# Gentian Customer Story - GCAL<sup>®</sup>

## The Assistance Publique-Hôpitaux de Paris (APHP Centre)

In the Gentian Customer Story we present how some of our valuable customers incorporate our assays in both clinical and laboratory settings to improve diagnostic efficiency.

### GCAL<sup>®</sup> - from COVID-19 clinical studies to a routine marker

The Assistance Publique-Hôpitaux de Paris (APHP Centre) is a world-renowned university hospital and a public health establishment in Greater Paris. Their 38 hospitals care for more than 10 million patients each year.

APHP started using GCAL<sup>®</sup> in 2020 to better identify patients developing a severe form of COVID-19. Today the assay is in routine testing for different diagnostic fields, including demand from internal medicine, ICU, emergency, hepato-gastroenterology, rheumatology and dermatology departments.

Prior to COVID-19 few of the clinicians at APHP were aware of plasma and serum calprotectin as a routine emergency biomarker. The interest in calprotectin came with a need for new biomarkers during the 1st COVID-19 wave. APHP was looking for biomarkers to complement existing markers (like CRP and IL-6) to better stratify disease severity and prognosis and decided to implement calprotectin. Calprotectin measurements were first included in clinical studies. With the availability of the automated and validated serum and plasma GCAL<sup>®</sup> Calprotectin Immunoassay the test was soon incorporated into clinical routine.

### GCAL<sup>®</sup> - now a routine inflammation marker on fully automated analysers

After seeing the strong association of calprotectin with COVID-19 severity and prognosis, the biomarker is now also perceived as a new informative biomarker of residual inflammation in autoimmune diseases and a valuable biomarker in clinical practice. APHP reports that GCAL<sup>®</sup> is easy to implement and use in routine practice on their Cobas c501 system, with demand from various clinical departments

*"Since we started performing GCAL<sup>®</sup> Calprotectin measurement on our fully automated analysers, the biomarker has become a new routine inflammation marker with strong informative value for all practitioners, in addition to other inflammatory biomarkers. Gentian's GCAL<sup>®</sup> Calprotectin is a robust assay in adequation with our laboratory quality requirements. Collaborating with Gentian in implementing the biomarker in our catalogue was easy and efficient. New fields of applications for calprotectin have raised in addition to the interest in ICU patients, such as for patients with vascularity, scleroderma and rheumatoid arthritis (RA)."*

Dr. Camille Chenevier-Gobeaux,  
APHP Centre – Université de Paris, France

### Gentian GCAL<sup>®</sup> - Calprotectin Immunoassay

GCAL<sup>®</sup>, the Gentian Calprotectin Immunoassay, is the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation.

The assay can be applied on a wide range of automated clinical chemistry analysers.



WE INNOVATE DIAGNOSTIC EFFICIENCY

Contact information: [marketing@gentian.com](mailto:marketing@gentian.com) • [www.gentian.com](http://www.gentian.com)

**gentian**